DARZALEX® SC practical guidance

DARZALEX® SC dosing and treatment schedules

  • Single-use vial, fixed dose of 1800 mg DARZALEX® and 30000 units of recombinant human hyaluronidase PH20 (ENHANZE® drug delivery technology)[1][2]

    • Fixed dose reduces wastage, risk of miscalculating dose and preparation time
  • Administration from the first dose of DARZALEX® SC treatment, and from the next scheduled dose in patients who are currently on DARZALEX® IV[1]
  • Vials do not require filtration or IV pump[1]
  • DARZALEX® solution for injection is a colourless-to-yellow liquid[1]
  • Treatment schedules with DARZALEX® SC remain the same, and DARZALEX® SC is available in all approved DARZALEX® IV indications[1]

Quick downloads

SC Checklist beginning of treatment

Includes a first use checklist of Darzalex® SC.

Darzalex® SC Practical Guide

Includes DARZALEX® SC handling and administration info, pre and post-injection medications, and more


AE: adverse event

IV: intravenous

MOA: mode of action

rHuPH20: recombinant human hyaluronidase

PH20 SC: subcutaneous

Para visualizar o IECRCM de Darzalex, veja aqui.


RCM DARZALEX ®. Acedido em março de 2022. Disponível em www.ema.europa.eu
Chari A et al. Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study. Oral presentation at the 59th American Society of Hematology annual meeting; December 9–12, 2017; Atlanta, GA; Abstract 838.
CP-287862 - March 2022